Vol.12No.8:9984

Ex-Accrebated Neurological and Brain Disorders in Covid-19 Pandemic – A Global Concern

Mohammad Azizur Rahman^{*1}, Nabidur Rahman¹, Umme Habiba², Jobayer Rahman³, Salman Shakil⁴, Kamrul Hsan⁵

Received date: August 08, 2021; Accepted date: November 12, 2021; Published date: November 22,

2021

Citation: Rahman A M, Rahman N, Habiba U, Rahman J, Shakil S, Hsan K (2021) Ex-Accrebated Neurological and Brain Disorders in Covid-19 Pandemic – A Global Concern, J Neurol Neurosci, Vol:7 No:10.

Abstract

Corona virus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome corona virus type 2 (SARS CoV-2), has been shattering the entire globe since December 2019. Although different medicinal, interceptive, social, political interventions have been adopted, no down toward rate of this pandemic has been reported elsewhere. Among different health-care sectors, the neurological and brain disorders have been mostly affected due to the COVID-19 pandemic. Present article points towards the mostly affected neurological and brain disorders associated with COVID-19 and recommends plausible guidelines that would be of immense importance to the COVID-19 sufferers and their care-givers and health-care providers as well as to the policy makers spread all over the world.

Keywords: Alzheimer's disease, brain disorders, COVID-19, neuro-psychiatiric complications, SARS CoV-2.

Introduction

Emerged at December, 2019, the corona virus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome corona virus type 2 (SARS CoV-2), has still remained the pandemic. The world health organization (WHO) has been formulating different strategies to combat COVID-19 since its inception but yet to reach the goal. In compliance with the WHO, different government and non-government organization also attempted but failed to hold back the COVID-19 consequences. COVID-19 has remained as the global threat in all aspects of sustenance: feeding, lodging, policy making, social security and economy as well as to the health care systems. Though multiple systems of the COVID-19 sufferers have been affected, the respiratory and nervous systems have undergone

the most notorious onslaught. The present article demonstrates the neurological and brain disorders mostly affected by the COVID-19.

Neurological and Brain Disorders affected by COVID-19

Alzheimer's disease

Alzheimer's disease (AD) is an age-onset neurodegenerative disorder and most of the patients show physiological complications at or after sixties. Though AD pathophysiology does not harbor COVID-19 patho-mechanism directly, there exists several indirect vulnerabilities of AD patients towards SARS-CoV-2 [1]. The angiotensin converting enzyme 2 (ACE2) receptor is the welcoming gate of SARS-CoV-2 entry to the respiratory and central nervous system (CNS) [1]. As both of these systems abound with ACE2 receptors, the CNS falls into extended vulnerability to SARS-CoV-2 load [1]. Most of the aged AD patients lack immunological shield against SARS-CoV-2 [2-3]. Besides, the AD patients undergo behavioral and personal alteration including declined memory and learning, cognitive impairment, irritability, mood disorder, bed-ridden and dependent on their family members and care-givers [2-3]. These factors add much insult to the already AD patient's injury. Due to COVID-19 overcoming regulatory strategies such as social distance maintenance, the care-givers can not provide full support to the AD patients; the AD patients can not remember the touching and washing recommendations; can not make sense of breathing problem and seek ventilation. AD patients already suffer from smell and odor problems that becomes heightened if simultaneously affected with COVID-19 [2-3]. At severe complications, AD patients become uncontrollable and tend to roam about but fail to trace their home and pose threat to themselves to become sufferer of COVID-19or to others for spreading COVID-19 [2-3].

¹Department of Biochemistry and Molecular Biology, Jahangirnagar University, Bangladesh.

² Department of Incepta Pharmaceuticals Limited, Bangladesh

³ Department of Enam Medical College and Hospital, Bangladesh.

⁴Department of Primeasia University, Bangladesh.

⁵ Department of Public Health and Informatics, Jahangirnagar University, Bangladesh.

^{*}Corresponding author: Mohammad Azizur Rahman, Department of Biochemistry and Molecular Biology, Jahangirnagar University, Bangladesh,Tel no: 008801727195484; Email: azizbmb@juniv.edu, azizurmcdp@gmail.com

Vol.12 No.8:9984

Other diseases

Besides AD, parkinson's disease (PD), multiple sclerosis, epilepsy, neuromuscular disorders, stroke, migraine, headache, Gullian-Barre syndrome are among the highly out broke ones during COVID-19 pandemic.

Conclusion

Pandemic COVID-19 is threat to the global community not only for its own complications, but also for its associated manifestations among whose neurological and brain disorders face the most vulnerable onslaught. Alzheimer's disease (AD) remains among the top-notch neurodegenerative disorders whose sufferers co-host the COVID-19 pathophysiology. Policymakers and health-care professionals and researchers should formulate strategies co-defending both of the global crises.

References

- Rahman MA, Islam K, Rahman S, Alamin M (2020). Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Molecular Neurobiology. 19:1–7.
- Rahman MA, Rahman MS, Alam N (2020). Heightened Vulnerability of Alzheimer's disease in COVID-19 Cataclysm and Putative Management Strategies. Annals of Alzheimer's disease and Care. 4(1): 027-029.
- 3. Rahman MA, Habiba, U (2021). COVID-19 and neuropsychiatric disorders: Common links and extended networks. J Neurol Neurol Sci Disord 7(1): 024-026.
- 4. Bhaskar S, Bradley S, Israeli-Korn S, Menon B, Chattu VK, Thomas P, Chawla J, Kumar R, Prandi P, Ray D, Golla S, Surya N, Yang H,

Martinez S, Ozgen MH, Codrington J, González EMJ, Toosi M, Hariya Mohan N, Menon KV, Chahidi A, Mederer Hengstl S. Chronic Neurology in COVID-19 Era: Clinical Considerations and Recommendations From the REPROGRAM Consortium. Front Neurol. 2020 Jun 24;11:664.

- Al Dossary N, AlMasoud MA. Journal of Neurology and Neuroscience.
- 6. Manca A, Martinez G, Cugusi L, Dragone D, Dvir Z, Deriu F. The surge of predatory open-access in neurosciences and neurology. Neuroscience. 2017 Jun 14;353:166-73. Kang EK, Baek MJ, Kim S, Paik NJ. Non-invasive cortical stimulation improves post-stroke attention decline. Restorative neurology and neuroscience. 2009 Jan 1;27(6):647-52.
- Haughey NJ, Nath A, Chan SL, Borchard AC, Rao MS, Mattson MP. Disruption of neurogenesis by amyloid β-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. Journal of neurochemistry. 2002 Dec;83(6):1509-24.
- Tang Y, Lu A, Aronow BJ, Wagner KR, Sharp FR. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. European Journal of Neuroscience. 2002 Jun;15(12):1937-52.
- Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS. Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of neuroscience research. 2003 Oct 15;74(2):278-85.
- 10. Zhu D, Wu X, Strauss KI, Lipsky RH, Qureshi Z, Terhakopian A, Novelli A, Banaudha K, Marini AM. N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway. Journal of neuroscience research. 2005 Apr 1;80(1):104-13.